Acticor Biotech SAS

ALACT

FR0014005OJ5

Biotechnology & Medical Research

End-of-day quote Euronext Paris Other stock markets 06:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
0.384 ^EUR	+3.78%		+14.29%	-86.76%

Apr. 30	Acticor Biotech SAS Announces Postponement in Publication of 2023 Annual Results	CI
Apr. 26	Acticor Biotech: rebound from the previous day's tumble	CF

Acticor Biotech SAS has completed an IPO in the amount of €15.508613 million.

October 27, 2021 at 12:00 am EDT

Acticor Biotech SAS has completed an IPO in the amount of €15.508613 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,178,176 PriceRange: €7.12

Latest news about Acticor Biotech SAS

Acticor Biotech SAS Announces Postponement in Publication of 2023 Annual Results	Apr. 30	CI
Acticor Biotech: rebound from the previous day's tumble	Apr. 26	CF
Acticor Biotech: Phase 2/3 study fails	Apr. 25	CF
Acticor Biotech SAS Announces Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment	Apr. 25	CI
Acticor Biotech: phase 2/3 results expected in May	Apr. 16	CF
Acticor Biotech Will Present the Clinical Results of Its Phase 2/3 Actisave Study in the Treatment of Stroke At Esoc 2024	Apr. 15	CI
Acticor Biotech: falls after capital increase	Mar. 15	CF
Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development	Mar. 15	MT
The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attack	Feb. 07	CI
Acticor: 'we are delighted to observe the market's reaction'.	Jan. 29	CF
Acticor Biotech continues to soar, hopes for stroke treatment	Jan. 24	CF
Acticor Biotech Announces Publication of ACTIMIS Clinical Study Results in the Lancet Neurology Journal	Jan. 23	CI
Acticor: capital increase at a significant discount	Nov. 28	CF
Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	Nov. 07	MT
ACTICOR BIOTECH Announces Timely Completed Patient Recruitment of Its Phase 2/3 Study in Stroke	Nov. 07	CI
Acticor Biotech SAS Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-26	CI
Acticor: modification of phase 2/3 study protocol	23-09-15	CF
Acticor Biotech: green light for UK study	23-09-08	CF
Acticor Biotech and University of Birmingham Announces The UK Regulatory Agency Approves the Protocol of LIBERATE Study, the First Clinical Trial Evaluating Glenzocimab for Heart Attacks	23-09-07	CI
Acticor Biotech: positive results for glenzocimab	23-08-31	CF
Acticor Biotech Announces Results of Its Collaboration with Brainomix Limited	23-08-31	CI
Acticor Biotech Announces Progress in Discussions with EU and US Regulatory Agencies	23-05-30	CI
Acticor Biotech SAS Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
Acticor Biotech Announces Enrollment of More Than 240 Patients in the ACTISAVE Phase 2/3 Study in Stroke and Regulatory Progress with the EMA and FDA	23-03-23	CI
Acticor Biotech Secures Funding Until November After EUR12 Million Equity Raise; Stock Sinks 17%	23-03-09	MT

Acticor Biotech is specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II/III clinical development (Glenzocimab).

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - European Stroke Organization Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

0.384 EUR

Average target price

1 EUR

Spread / Average Target

+160.42%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ACTICOR BIOTECH SAS	-86.76%	5.43M
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B

Bio Therapeutic Drugs